Product Name

Dabigatran Etexilate Mesylate

General description

Dabigatran Etexilate Mesylate is the prodrug of dabigatran.

Synonym

ethyl 3-[[2-[[4-[(Z)-N'-hexoxycarbonylcarbamimidoyl]anilino]methyl]-1-methylbenzimidazole-5-carbonyl]-pyridin-2-ylamino]propanoate; methanesulfonic acid

Purity

≥98.0%(HPLC)

CAS Number

872728-81-9

Formula

C³⁵H⁴⁵N⁷O⁸S

Molecular Weight

723.846

Suitability

BioReagent, suitable for cell culture, etc.

l  Physical and Chemical Information

Appearance

Pale yellow or yellow solid

l  Biological Information

Biochem/Physiol   Actions

Dabigatran Etexilate Mesylate is an orally available mesylate salt form of the etexilate prodrug of dabigatran, a benzimidazole and direct thrombin inhibitor with anticoagulant activity. Upon administration, dabigatran etexilate is hydrolyzed by esterases and is converted into dabigatran. Dabigatran reversibly binds to and inhibits the activity of thrombin, a serine protease that converts fibrinogen into fibrin. This disrupts the coagulation cascade and inhibits the formation of blood clots.

Application

Antithrombins

l  Packaging & Storage

Packaging

50mg; 250mg; 1g

Storage temp.

0-5℃

l  Precautions and Disclaimer

This   product is for R&D use only, not for drug, household, or other uses.

l  References

1.    http://www.drugbank.ca

2.    https://ncit.nci.nih.gov

3.    https://www.ncbi.nlm.nih.gov